Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab + Chemo in Locally Advanced Lung Adenocarcinoma
NCT01588704Phase 2Completed
- Start
- Apr 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in lung adenocarcinoma. Primary endpoint: Resectability rate at 3 months. Started Apr 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01588704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588704.